SCHEMBL16811751

SCHEMBL16811751

COc1ccccc1[C@H](C)C(=O)OC(C)(C)C

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ITGA4 P13612 1/20 0.47
ITGB7 P26010 1/20 0.47
KMT2A Q03164 1/20 0.44
POLB P06746 1/20 0.43
HTT P42858 1/20 0.43
NPSR1 Q6W5P4 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
PTGS1 P23219 1/20 0.42
PTGS2 P35354 1/20 0.42
LPAR1 Q92633 3/20 0.41
CA1 P00915 4/20 0.41
CA2 P00918 4/20 0.41
ACHE P22303 2/20 0.41
AKR1C3 P42330 1/20 0.40
AKR1C2 P52895 1/20 0.40
KCNK3 O14649 1/20 0.40
KCNK9 Q9NPC2 1/20 0.40
KDM4E B2RXH2 2/20 0.39
LMNA P02545 2/20 0.39
ALOX12 P18054 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28554206 0.83 ITGA4 (0.47) ITGA4ITGB7KMT2APOLBHTT
SCHEMBL1826004 0.83 ITGA4 (0.35) ITGA4ITGB7CA1CA2ACHE
SCHEMBL14721160 0.83 ESR1 (0.42) ITGA4ITGB7KMT2AL3MBTL1LMNA
SCHEMBL5215418 0.83 ESR1 (0.42) ITGA4ITGB7KMT2AL3MBTL1LMNA
SCHEMBL5541713 0.82 LPAR1 (0.49) KMT2APOLBHTTNPSR1L3MBTL1
SCHEMBL2173300 0.81 MAOB (0.42) ITGA4ITGB7KMT2A
SCHEMBL7746373 0.81 GABRA1 (0.47) ITGA4ITGB7KMT2APOLBPTGS1
SCHEMBL16410353 0.80 APP (0.37) KMT2ALMNACYP1A2
SCHEMBL1820753 0.80 MAPT (0.43) ITGA4ITGB7KMT2AHTTL3MBTL1
SCHEMBL19024635 0.79 L3MBTL1 (0.46) KMT2APOLBHTTNPSR1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9512155-B2 Chiral phosphines for palladium-catalyzed asymmetric α-arylation of ester enolates to produce tertiary stereocenters in high enantioselectivity NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-12-06 US disclosed
US-9512155-B2 Chiral phosphines for palladium-catalyzed asymmetric α-arylation of ester enolates to produce tertiary stereocenters in high enantioselectivity NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2016-12-06 US disclosed
US-20150166586-A1 CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2015-06-18 US disclosed
US-20150166586-A1 CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY NANYANG TECHNOLOGICAL UNIVERSITY (SG) 2015-06-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150166586-A1 CHIRAL PHOSPHINES FOR PALLADIUM-CATALYZED ASYMMETRIC ALPHA-ARYLATION OF ESTER ENOLATES TO PRODUCE TERTIARY STEREOCENTERS IN HIGH ENANTIOSELECTIVITY EPHA8, DAGLA, TEC ITGA4 1069/4885ITGB7 2117/4885KMT2A 120/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.